THE APEX TIMES
A new real-world comparative effectiveness analysis of Moderna’s mNEXSPIKE in U.S. Veterans age 65 and older was published in JAMA Network Open, adding another data point for how the COVID-19 mRNA vaccine performs outside clinical trials.
Moderna said a real-world comparative effectiveness analysis of its COVID-19 vaccine, mNEXSPIKE, has been published in JAMA Network Open. The paper focuses on adults aged 65 and older and uses data from U.S. Veterans, a population that is often used to evaluate vaccine outcomes in routine clinical settings.
According to Moderna’s announcement, the study analyzed more than 294,000 U.S. Veterans aged 65 and older. The research compared vaccinated and unvaccinated groups to assess outcomes in everyday use rather than under trial protocols, a distinction that is often important when interpreting vaccine performance because real-world populations include a wider range of underlying health conditions and care patterns.
Moderna said the analysis found mNEXSPIKE was associated with a 35% reduction for a key endpoint in the study. The company did not specify in its announcement what outcome the 35% figure refers to, nor did it provide additional details such as confidence intervals or adjusted risk estimates within the posted summary.
JAMA Network Open is a peer-reviewed medical journal published by the JAMA Network. Publication there generally means the study underwent editorial and peer review, which can strengthen credibility compared with company claims alone, though readers typically still need to examine the full paper for methods, endpoints, and limitations.
The mNEXSPIKE label refers to Moderna’s mRNA-based COVID-19 vaccine product. Comparative effectiveness studies like this one can help supplement clinical trial findings by answering how a vaccine performs in broader, older populations where immune response, comorbidities, and exposure risks vary substantially.
In the context of an aging population, outcomes in adults 65 and older are a central concern for vaccine programs. Real-world analyses can also inform how stakeholders weigh benefits against risks and how they think about dosing strategies and expected impact over time, particularly as circulating variants and vaccination histories evolve.
Moderna did not disclose, in the information accompanying the publication announcement, specifics that readers often look for in comparative-effectiveness papers, including how vaccination status was determined, how the study handled confounding factors, whether outcomes were hospitalization, severe disease, or another endpoint, and whether results differed by subgroup such as comorbidity burden or prior vaccination history.
What to watch next is whether Moderna, or the authors of the JAMA Network Open paper, will provide more granular results in subsequent materials, such as subgroup analyses, full endpoint definitions, and the statistical adjustments used. Those details will matter for understanding how broadly the 35% figure applies and how it should be interpreted relative to other evidence.
A strong quarter from CoreWeave, a major cloud provider for AI compute, helped quiet worries that technology infrastructure spending could cool. Shares tied to AI chips and networking moved higher alongside the sentiment shift.
The ride-hailing and delivery platform is expanding an expanded McDonald’s partnership across 14 markets, positioning delivery growth as a lever for broader Uber Direct adoption and customer engagement.
A major downgrade cut Nvidia’s target price by about 60 percent, while other Wall Street analysts held bullish outlooks and pointed to higher upside targets.
A Bank of America analyst adjusted Eli Lilly’s price target, saying attention should broaden beyond the company’s weight-loss blockbuster franchise as it prepares for its December Innovation Day.
A new report says Tesla and SpaceX have each formed special committees to review a potential all-stock merger, a move that comes as Tesla prepares to unveil its next-generation Roadster.
A new report says Visa is integrating with Monad to expand the flexibility of its stablecoin settlement network, pointing to surging settlement activity and growing institutional interest in faster, programmable payment flows.
Bank of America sees upside in Qualcomm’s efforts to position the chipmaker as a broader supplier to AI data centers, while still expressing caution on what near-term execution can deliver.
A Wall Street note captured a split view of Advanced Micro Devices, with higher profit expectations offset by a lower price target amid recent market pressure.
A Yahoo Finance report says Cathie Wood’s ARK Investment Management reduced its Amazon position while adding to a basket of aerospace-related names after strong trading activity around a rocket launch company.
A recent pullback has renewed debate over whether Exxon Mobil’s valuation properly reflects its current deal slate, including new activity tied to Venezuela, despite the company’s strong multi-year run.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...